TOT BIOPHARM Co Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TOT BIOPHARM Co Ltd
Private Company Edition: Biomedtracker found that 53% of financings during the first quarter were venture capital deals versus 32% in Q1 of last year. Also, Qiming closed a $260m fund, Transition Bio raised a $50m series A round, ProfoundBio completed a $70m series A+ and MycoMedica raised $60m.
The Dutch firm’s dream to become the number one antibody drug conjugate technology provider by 2023 has been bolstered by a flurry of recent strategic collaborations, including one with MacroGenics.
After listing on the Hong Kong stock exchange in late 2019, China’s Tot Biopharm has delivered its first antibody drug approval, with its Pusintin (bevacizumab) biosimilar to Avastin.
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.